The Combined Effects of the 5-HTTLPR and 5-HTR1A Genes Modulates the Relationship Between Negative Life Events and Major Depressive Disorder in a Chinese Population
Overview
Affiliations
Background: Serotonin transporter (5-HTT) and 5-HT receptor (5-HTR) involved in the neurotransmission of 5-HT may play an important role in the development of major depression disorder (MDD). Several lines of evidence suggested that the gene-environment interaction may confer susceptibility to depression. The aim of this study is to analyze the combined effect of four serotonin-related genes and two environmental factors on MDD in a Chinese population.
Methods: This study recruited a total of 401 patients with MDD and 391 age- and gender-matched control subjects. They were all Chinese Han origin. Negative life events and objective social supports were assessed using standard rating scales. Six polymorphisms in the four serotonin-related genes (5-HTT, 5-HTR1A, 5-HTR1B and 5-HTR2A) were selected to detect. The analyses of the gene-environment interactions were performed by the Multifactor Dimensionality Reduction (MDR).
Results: Allelic associations between patients with MDD and controls were observed for the polymorphism of 5-HTTLPR and for rs6295 at the 5-HTR1A locus. The 5-HTTLPR polymorphism was associated with negative life events on MDD. A three-way interaction between the 5-HTTLPR polymorphism, rs6295 and negative life events on MDD was found in the individuals aged from 20 years to 29 years. In addition, the individuals carrying the L/L genotype of 5-HTTLPR could be susceptible to MDD when exposed to negative life events.
Conclusions: The 5-HTTLPR polymorphism may modify the interaction between negative life events and MDD in the Chinese population. To our knowledge, this is the first report on the combined effect for the 5-HTTLPR polymorphism and 5-HTR1A genes on modifying the response to negative life events conferring susceptibility to MDD in the 20-29 year group.
Wu H, Zhu S, Zhang L, Shen B, Xu L World J Psychiatry. 2024; 14(10):1573-1582.
PMID: 39474388 PMC: 11514568. DOI: 10.5498/wjp.v14.i10.1573.
Nair B, Khan S, Naidoo N, Jannati S, Shivani B, Banerjee Y Front Psychol. 2024; 15:1240791.
PMID: 38544521 PMC: 10966386. DOI: 10.3389/fpsyg.2024.1240791.
Galfalvy H, Shea E, de Vegvar J, Pantazatos S, Huang Y, Burke A Br J Psychiatry. 2023; 223(3):415-421.
PMID: 37395098 PMC: 10514224. DOI: 10.1192/bjp.2023.13.
Singh P, Srivastava A, Guin D, Thakran S, Yadav J, Chandna P Int J Neuropsychopharmacol. 2023; 26(10):692-738.
PMID: 36655406 PMC: 10586057. DOI: 10.1093/ijnp/pyad001.
Ellerbrock I, Sandstrom A, Tour J, Fanton S, Kadetoff D, Schalling M Mol Brain. 2021; 14(1):81.
PMID: 33980291 PMC: 8117625. DOI: 10.1186/s13041-021-00789-4.